PDCD1 and neoplasm: Future strategies may overcome immunotherapy resistance through combinational approaches, for example, combining PD-1/PD-L1 blockade with interventions that regulate membrane cholesterol metabolism or inhibit PD-L1 enrichment within rafts, thereby synergistically relieving tumor-mediated immunosuppression and improving the efficacy of CRC immunotherapy.